A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Name: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Published: 2024
License: Public Domain

AstraZeneca · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

non-small-cell-lung-cancer paclitaxel pembrolizumab

non-small cell lung cancer, artemide-lung02, rilvegostomig (azd2936), non-small cell lung cancer (nsclc), bi-specific antibody, t-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (tigit), programmed death-ligand 1 (pd-l1), pembrolizumab, carboplatin, paclitaxel, nab-paclitaxel, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Related documents